DICE Therapeutics, Inc. (NASDAQ:DICE) Short Interest Up 5.1% in February

DICE Therapeutics, Inc. (NASDAQ:DICE – Get Rating) was the target of a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 5,740,000 shares, a growth of 5.1% from the January 31st total of 5,460,000 shares. Approximately 18.7% of the shares of the company are short sold. Based on an average trading volume of 391,100 shares, the days-to-cover ratio is presently 14.7 days.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Cowen assumed coverage on DICE Therapeutics in a research report on Wednesday, March 1st. They issued an “outperform” rating for the company. Cowen initiated coverage on DICE Therapeutics in a research report on Wednesday, March 1st. They set an “outperform” rating for the company. Guggenheim began coverage on DICE Therapeutics in a research note on Tuesday, November 15th. They set a “buy” rating and a $65.00 price target for the company. Finally, TD Cowen began coverage on DICE Therapeutics in a research note on Wednesday, March 1st. They issued an “outperform” rating for the company. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $65.86.

Hedge Funds Weigh In On DICE Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Voya Investment Management LLC lifted its position in DICE Therapeutics by 161.1% in the 4th quarter. Voya Investment Management LLC now owns 29,293 shares of the company’s stock valued at $914,000 after acquiring an additional 18,074 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in shares of DICE Therapeutics by 3.1% during the 4th quarter. Alliancebernstein L.P. now owns 26,900 shares of the company’s stock valued at $839,000 after buying an additional 800 shares during the period. Metropolitan Life Insurance Co NY lifted its holdings in shares of DICE Therapeutics by 20.3% during the 4th quarter. Metropolitan Life Insurance Co NY now owns 2,223 shares of the company’s stock valued at $69,000 after buying an additional 375 shares during the period. MetLife Investment Management LLC lifted its holdings in shares of DICE Therapeutics by 18.4% during the 4th quarter. MetLife Investment Management LLC now owns 18,851 shares of the company’s stock valued at $588,000 after buying an additional 2,930 shares during the period. Finally, Jane Street Group LLC lifted its holdings in shares of DICE Therapeutics by 205.3% during the 4th quarter. Jane Street Group LLC now owns 16,118 shares of the company’s stock valued at $503,000 after buying an additional 31,418 shares during the period. 91.51% of the stock is owned by institutional investors.

DICE Therapeutics Stock Performance

DICE stock opened at $28.51 on Wednesday. DICE Therapeutics has a fifty-two week low of $12.64 and a fifty-two week high of $45.99. The business’s 50 day moving average price is $30.45 and its two-hundred day moving average price is $28.87. The company has a market capitalization of $1.36 billion, a price-to-earnings ratio of -13.42 and a beta of 0.71.

About DICE Therapeutics

(Get Rating)

DICE Therapeutics, Inc, a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics.